Infectious Diseases Therapeutic Market projected to grow with significant CAGR over the forecast per
Posted: May 07, 2018
Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. These infectious diseases transmitted from one individual to other either by direct or indirect contact. The drugs used for the infectious diseases are antibiotics, antiviral, and anti-parasitic medications among others. Infectious disease therapeutics acts directly on organisms or helps body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others.
Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct-acting antiviral drugs are fueling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increasing number of generic alternatives hindering the market revenue of infectious disease therapeutics market.
A sample of this report is available upon request @
Infectious disease therapeutics market is categorized as-
1. Drug class
2. Type of disease
To view TOC of this report is available upon request @
Hospital pharmacies, retail pharmacies and others.
And lastly, the geographically infectious disease therapeutics market has been divided into following regions for e.g. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the infectious disease therapeutics market owing to high prevalence rates of infectious diseases and rise in geriatric population. In the last few years, there was an increase in the use of antibiotics in Asian countries like India and China and some parts of Africa. Factors such as booming infrastructure in healthcare, government initiatives, etc. boosting the infectious diseases therapeutics market. Some of the key players in infectious disease therapeutics market are GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (Switzerland), AbbVie Inc. (U.S.), Astellas Pharma Inc. (Japan), AstraZeneca (U.K.), Bayer AG (Germany), Chimerix Inc. (U.S.), Eli Lilly and Company (U.S.), Isis Pharmaceuticals (U.S.), Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan), and Sanofi S.A. (France) and to name a few. In 2017, Gilead’s Vosevi oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus. In 2015, USFDA approved Cresemba (Isavuconazonium sulfate), an anti-fungal drug for treating adults with invasive aspergillosis and invasive mucormycosis.
Need more information about this report @
Market players are focusing on mergers, collaborations, and partnerships to increase market share. For e.g. in 2016, Pfizer obtained AstraZeneca’s last stage small molecules anti-infectives business for development and commercialization outside the US. Some of the pipeline anti-infectives include Avycaz (Ceftazidime and Avibactam), Bictegravir (Anti HIV), Cabotegravir (Anti HIV). On the contrary, patent expiration of blockbuster anti-infectives medications such as Tamiflu, Cubicin, and Ambisome is expected to negatively affect the infectious disease therapeutics market.
Get access to full summary @
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
152 – 160 City Road,
London EC1V 2NX
Website @ https://www.precisionbusinessinsights.com